• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
How can the results of Health Technology Assessment (HTA) evaluations applied to vaccinations be communicated to decision-makers and stakeholders? The ISPOR Rome Chapter Project.如何将应用于疫苗接种的卫生技术评估(HTA)评价结果传达给决策者和利益相关者?国际药物经济学与结果研究协会(ISPOR)罗马分会项目。
J Prev Med Hyg. 2015;56(4):E150-4.
2
[The economic value of vaccinations: a systematic review of Italian economic evaluations and HTA reports].[疫苗接种的经济价值:对意大利经济评估和卫生技术评估报告的系统评价]
Ig Sanita Pubbl. 2017 Sep-Oct;73(5):453-471.
3
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.避免和识别健康技术评估模型中的错误:定性研究和方法学综述。
Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107. doi: 10.3310/hta14250.
4
Health technology assessment of medical devices: What is different? An overview of three European projects.医疗设备的卫生技术评估:有何不同?三个欧洲项目概述。
Z Evid Fortbild Qual Gesundhwes. 2015;109(4-5):309-18. doi: 10.1016/j.zefq.2015.06.011. Epub 2015 Jul 26.
5
Community views and perspectives on public engagement in health technology assessment decision making.社区对公众参与卫生技术评估决策的看法和观点。
Aust Health Rev. 2017 Mar;41(1):68-74. doi: 10.1071/AH15221.
6
Public preferences for engagement in Health Technology Assessment decision-making: protocol of a mixed methods study.公众参与卫生技术评估决策的偏好:一项混合方法研究的方案
BMC Med Inform Decis Mak. 2015 Jul 14;15:52. doi: 10.1186/s12911-015-0176-0.
7
Best-worst scaling to assess the most important barriers and facilitators for the use of health technology assessment in Austria.运用最佳-最差标度法评估奥地利卫生技术评估使用过程中最重要的障碍因素和促进因素。
Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):223-232. doi: 10.1080/14737167.2017.1375407. Epub 2017 Sep 8.
8
Integrating patients and social aspects into health technology assessment将患者和社会因素纳入卫生技术评估
9
Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary.中等收入国家卫生技术评估实施的能力建设:以匈牙利为例。
Value Health Reg Issues. 2013 Sep-Oct;2(2):264-266. doi: 10.1016/j.vhri.2013.06.002. Epub 2013 Jul 25.
10
The HTA Core Model-10 Years of Developing an International Framework to Share Multidimensional Value Assessment.卫生技术评估核心模型——构建用于分享多维价值评估的国际框架的十年历程
Value Health. 2017 Feb;20(2):244-250. doi: 10.1016/j.jval.2016.12.010.

引用本文的文献

1
[Not Available].[无可用内容]。
J Prev Med Hyg. 2025 Apr 15;66(1 Suppl 2):E1-E56. doi: 10.15167/2421-4248/jpmh2025.66.1s2. eCollection 2025 Apr.
2
Influenza vaccination: from epidemiological aspects and advances in research to dissent and vaccination policies.流感疫苗接种:从流行病学层面、研究进展到异议与疫苗接种政策
J Prev Med Hyg. 2016;57(1):E1-4.

本文引用的文献

1
Evaluation of the economic burden of Herpes Zoster (HZ) infection.带状疱疹(HZ)感染的经济负担评估。
Hum Vaccin Immunother. 2015;11(1):245-62. doi: 10.4161/hv.36160.
2
Effectiveness of vaccination against varicella in children under 5 years in Puglia, Italy 2006-2012.2006 - 2012年意大利普利亚大区5岁以下儿童水痘疫苗接种的有效性
Hum Vaccin Immunother. 2015;11(1):214-9. doi: 10.4161/hv.36153. Epub 2014 Nov 1.
3
Impact of universal vaccination against varicella in Italy.意大利水痘普遍接种疫苗的影响。
Hum Vaccin Immunother. 2015;11(1):63-71. doi: 10.4161/hv.34311. Epub 2014 Nov 1.
4
New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers.新型与旧型B群脑膜炎球菌疫苗:新型疫苗如何使婴幼儿受益。
Indian J Med Res. 2013 Dec;138(6):835-46.
5
Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010-2013.迈向13价肺炎球菌结合疫苗普遍接种:2010 - 2013年意大利在7价肺炎球菌结合疫苗(PCV7)和13价肺炎球菌结合疫苗(PCV13)过渡时期的有效性
Hum Vaccin Immunother. 2014;10(1):33-9. doi: 10.4161/hv.26650. Epub 2013 Oct 7.
6
Economic evaluation of Varicella vaccination: results of a systematic review.水痘疫苗的经济学评估:一项系统评价的结果
Hum Vaccin Immunother. 2013 Sep;9(9):1932-42. doi: 10.4161/hv.25228. Epub 2013 Jul 3.
7
Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits.意大利乙型肝炎疫苗全民接种计划实施 20 年的经济学分析:事后评估和未来收益预测。
Hum Vaccin Immunother. 2013 May;9(5):1119-28. doi: 10.4161/hv.23827. Epub 2013 Feb 1.
8
Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.意大利新型成人肺炎球菌疫苗接种策略的成本效益
Hum Vaccin Immunother. 2013 Mar;9(3):699-706. doi: 10.4161/hv.23268. Epub 2013 Jan 7.
9
23-valent pneumococcal polysaccharide vaccine (PPV23) for the prevention of invasive pneumococcal diseases (IPDs) in the elderly: is it really effective?用于预防老年人侵袭性肺炎球菌疾病(IPD)的23价肺炎球菌多糖疫苗(PPV23):它真的有效吗?
J Prev Med Hyg. 2012 Jun;53(2):101-3.
10
Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly.成人和老年人季节性和大流行性流感的临床和社会经济学影响。
Hum Vaccin Immunother. 2012 Jan;8(1):21-8. doi: 10.4161/hv.8.1.17622. Epub 2012 Jan 1.

如何将应用于疫苗接种的卫生技术评估(HTA)评价结果传达给决策者和利益相关者?国际药物经济学与结果研究协会(ISPOR)罗马分会项目。

How can the results of Health Technology Assessment (HTA) evaluations applied to vaccinations be communicated to decision-makers and stakeholders? The ISPOR Rome Chapter Project.

作者信息

Gasparini R, Mennini F S, Panatto D, Bonanni P, Bechini A, Ricciardi W, DE Waure C, Marcellusi A, Cicchetti A, Ruggeri M, Boccalini S

机构信息

Department of Health Sciences, University of Genoa, Italy;

Faculty of Economics Centre for Economic and International Studies (CEIS) -Economic Evaluation and HTA (EEHTA), University of Rome, Italy;

出版信息

J Prev Med Hyg. 2015;56(4):E150-4.

PMID:26900329
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4753815/
Abstract

HTA is considered the most comprehensive and transparent method of supporting decision-makers in their choices in Public Health. HTA on vaccines is being performed by many experts. However, they often present their studies to colleagues, but not to decisionmakers, who should be the main target and current users. It is therefore crucial to improve the transfer of scientific data to decision- makers and all stakeholders. The aims of the present project are: 1) to set up a team of experts to collect economic evaluations and HTA studies on vaccines and assess their actual use in decision-making processes; 2) to constitute regional working groups in order to identify the critical aspects of the communication process and identify the most appropriate method of data transfer. Systematic reviews of economic evaluations and HTA on vaccines and their actual use in decision-making will be used to draw up the basic documents for discussion by the 3 regional working boards. The working groups will discuss the current scientific evidence and communication methods and will try to implement a model of technology assessment with well-defined and objective criteria, in order to better fit pharmaco-economic and HTA methods to the field of vaccinations. Improving the transfer of HTA results to stakeholders, particularly decision-makers, will enable decisions to be taken on the basis of scientific evidence, and appropriate, sustainable actions to be undertaken.

摘要

卫生技术评估被认为是在公共卫生领域支持决策者做出选择的最全面、最透明的方法。许多专家都在进行疫苗方面的卫生技术评估。然而,他们往往将研究成果呈现给同行,而非决策者,而决策者才应是主要目标群体和当前使用者。因此,改善科学数据向决策者及所有利益相关者的传递至关重要。本项目的目标如下:1)组建一个专家团队,收集关于疫苗的经济评估和卫生技术评估研究,并评估其在决策过程中的实际应用;2)成立区域工作组,以确定沟通流程的关键环节,并确定最合适的数据传递方法。对疫苗的经济评估和卫生技术评估及其在决策中的实际应用进行系统评价,将用于起草3个区域工作委员会讨论的基础文件。各工作组将讨论当前的科学证据和沟通方法,并尝试实施一个具有明确、客观标准的技术评估模型,以使药物经济学和卫生技术评估方法更适用于疫苗接种领域。改善卫生技术评估结果向利益相关者,特别是决策者的传递,将使决策能够基于科学证据做出,并采取适当、可持续的行动。